Home/Pipeline/Undisclosed PPI Inhibitor Program(s)

Undisclosed PPI Inhibitor Program(s)

Oncology

PreclinicalActive

Key Facts

Indication

Oncology

Phase

Preclinical

Status

Active

Company

QuBind

About QuBind

QuBind is a private, preclinical-stage biotech leveraging a proprietary platform to discover small molecules that disrupt critical protein-protein interactions in oncology. Operating in the high-potential but challenging field of PPI inhibition, the company is likely pursuing novel targets beyond traditional enzyme active sites. As a young, venture-backed firm in a major biotech hub, its success hinges on validating its platform through lead optimization and advancing a candidate into clinical trials to demonstrate proof-of-concept.

View full company profile

Therapeutic Areas

Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active